Prodotti della ricerca

 

UNICA IRIS Institutional Research Information System

IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Cagliari dal mese di luglio 2015.

Mostra risultati da 21 a 39 di 39
 < precedente 
TitoloData di pubblicazioneAutore(i)RivistaEditore
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model.2011CARTA A; PISANU A; FRAU L; SPIGA S; CARBONI ESOC. NEUROSCI. ABSTR., 41TH ANNUAL MEETING SOCIETY FOR NEUROSCIENCE, WASHINGTON D.C., 12-16 NOVEMBRE 2011Society for Neuroscience
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra2010Khairnar A; Frau L; Fenu S; Morelli M
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors2010Morelli M; Frau L; Khairnar A; Fenu SSOCIETY FOR NEUROSCIENCE
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease2010CARTA A; FENU S; FRAU L; IBBA M; WARDAS J; CABONI P; CARBONI ESOCIETY FOR NEUROSCIENCESociety for Neurosciences
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain2010KHAIRNAR A; PLUMITALLO A; FRAU L; SCHINTU N; MORELLI MNEUROTOXICITY RESEARCH
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression2010Carta AR; Frau L; Pinna A; Morelli M.EXPERIMENTAL NEUROLOGY
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease2009SCHINTU N; FRAU L; IBBA M; CABONI P; GARAU A; CARBONI E; CARTA AREUROPEAN JOURNAL OF NEUROSCIENCE
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain2009Khairnar A; Plumitallo A; Frau L; Morelli M
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease2009SCHINTU N; FRAU L; IBBA M; GARAU A; CARBONI E; CARTA ARNEUROTOXICITY RESEARCH
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain2009Khairnar A; Plumitallo A; Frau L; Morelli M
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat2009Carta, Annarosa; Frau, Lucia; Pinna, A; Morelli, MicaelaSpringer
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat2008CARTA AR; FRAU L; PINNA A; PONTIS S; SIMOLA N; SCHINTU N; MORELLI MSYNAPSE
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence2008CARTA A; FRAU L; PONTIS S; PINNA A; MORELLI MPARKINSONISM & RELATED DISORDERS
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 2008Carta A; Schintu N; Frau L; Ibba M; Carboni ESOCIETY FOR NEUROSCIENCE
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2008Frau L; Schintu N; Carboni E; Ibba M; Carta ARSOCIETY FOR NEUROSCIENCE
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE2008FRAU L; SCHINTU N; CARBONI E; SILVAGNI A; CARTA AR
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs2008CARTA ANNA R; FRAU L; PINNA ANNALISA; MORELLI MICAELA
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats2007TRONCI E; SIMOLA N; BORSINI F; SCHINTU N; FRAU L; CARMINATI P; MORELLI MEUROPEAN JOURNAL OF PHARMACOLOGY
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease2006MORELLI M; CARTA A.R; PINNA A; PONTIS S; FRAU L; SIMOLA NMOVEMENT DISORDERS
   
credits unica.it | accessibilità Università degli Studi di Cagliari
C.F.: 80019600925 - P.I.: 00443370929
note legali | privacy

Nascondi la toolbar